Compare

Alcon/$ALC

1D1W1M3M6MYTD1Y5YMAX

About Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Health
Primary listing
NYSE
Employees
25,000
Headquarters
Geneva, Switzerland
Website
www.alcon.com

Alcon Metrics

BasicAdvanced
$34B
53.34
$1.31
0.70
$0.23
0.33%

What the Analysts think about Alcon

Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Analyst projections of the future price of Alcon stock.

Bulls say / Bears say

Second-quarter sales rose 7% at constant currency, and Alcon raised its 2026 core operating margin and EPS growth outlook. This suggests recent execution is translating into stronger earnings expectations. (Reuters)
UNITY-led equipment sales grew 25% at constant currency in the second quarter, giving Alcon a fast-growing surgical product line and a base for further placements. (Alcon)
Vision Care is another source of momentum: ocular health sales rose 12% and contact lens sales 5% at constant currency in the second quarter. Alcon also reported record global contact lens share, supported by recent product launches. (Alcon, The Motley Fool)
Implantables grew just 1% at constant currency in the second quarter, with Alcon citing competitive pressure on intraocular lenses and lower surgical glaucoma sales. That limits growth in a key surgical franchise despite PanOptix Pro momentum. (Alcon)
Cataract procedure volumes were flat in the US and grew only at a low-single-digit pace globally in the second quarter. Weak procedure growth could constrain sales of lenses and related surgical products. (The Motley Fool)
Alcon expects tariffs to reduce 2026 results by $40 million to $90 million even after mitigation and an anticipated refund. Its substantial US sales and manufacturing exposure leaves earnings vulnerable if trade costs persist or rise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.

Alcon Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Alcon Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Alcon News

AllArticlesVideos

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Business Wire7 days ago

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Business Wire2 weeks ago

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.